Drug Topics March 8, 2024
Study results demonstrated the efficacy of semaglutide (Wegovy) in reducing cardiovascular risks in adults with overweight or obesity without diabetes.
Semaglutide (Wegovy) has earned FDA approval for a new indication: in addition to treating overweight and obesity in adults and children aged 12 years and older, Novo Nordisk’s injection can now be used to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either overweight or obesity.1,2
The FDA granted the glucagon-like peptide-1 (GLP-1) receptor agonist a priority review designation for this indication.
The agency’s decision comes after an analysis of data from the multicenter, multinational, double-blind, placebo-controlled, phase 3 SELECT clinical trial (NCT03574597). These data were presented in a late-breaking abstract at...
Today's Sponsors
Today's Sponsor